These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 23289822

  • 1. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [Abstract] [Full Text] [Related]

  • 2. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
    Mathieu C, Bode BW, Franek E, Philis-Tsimikas A, Rose L, Graungaard T, Birk Østerskov A, Russell-Jones D.
    Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
    [Abstract] [Full Text] [Related]

  • 4. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
    Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco AM, Kinduryte O, Danne T.
    Pediatr Diabetes; 2015 May; 16(3):164-76. PubMed ID: 25683037
    [Abstract] [Full Text] [Related]

  • 5. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
    Le Floch JP, Lévy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, Eschwege E, Fontaine P, Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group.
    Diabetes Care; 2009 Jan; 32(1):32-7. PubMed ID: 18945928
    [Abstract] [Full Text] [Related]

  • 6. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J, Christiansen JS.
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [Abstract] [Full Text] [Related]

  • 7. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C.
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [Abstract] [Full Text] [Related]

  • 8. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
    Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV.
    Endocr Pract; 2011 Dec; 17(6):862-6. PubMed ID: 21550949
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).
    Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K.
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [Abstract] [Full Text] [Related]

  • 10. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 11. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
    Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, King A, Mersebach H, Davies M.
    Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
    [Abstract] [Full Text] [Related]

  • 12. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
    Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.
    Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
    [Abstract] [Full Text] [Related]

  • 13. Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial.
    Petit-Bibal C, Rothenbuhler A, Lucchini P, Aboumrad B, Castell AL, Le Fur S, Bougnères P.
    Pediatr Diabetes; 2015 Aug; 16(5):345-53. PubMed ID: 24888575
    [Abstract] [Full Text] [Related]

  • 14. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S, Dizdar OS, Oz Gul O, Guclu M, Unal OK, Tuncel E, Erturk E, Imamoglu S, Ersoy C.
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [Abstract] [Full Text] [Related]

  • 15. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
    Davies M, Sasaki T, Gross JL, Bantwal G, Ono Y, Nishida T, Tojjar D, Seino H.
    Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
    Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao PV, Deenadayalan S, Ekelund M, Larsen SF, Danne T.
    Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
    [Abstract] [Full Text] [Related]

  • 17. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S, Facchinetti A, Bonora BM, Mariano V, Boscari F, Cipponeri E, Maran A, Avogaro A, Fadini GP, Bruttomesso D.
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [Abstract] [Full Text] [Related]

  • 18. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK, BOOST: Intensify Premix I Investigators.
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [Abstract] [Full Text] [Related]

  • 19. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
    Abalı S, Turan S, Atay Z, Güran T, Haliloğlu B, Bereket A.
    Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, Niemeyer M, Seino H, BEGIN BB T1 Study Group.
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.